Company / Capital Expenditures
Terns Pharmaceuticals, Inc. Capital Expenditures History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$42.0K
FY2024
5-year range
$42.0K / $584.0K
FY2020-FY2024
Trend
-19.2%
vs FY2023
Sector context
#182 of 195
Health Care
What the data says
Among 195 Health Care companies, Terns Pharmaceuticals, Inc. is in the bottom 7% for capital expenditures. Capital Expenditures has declined for 4 consecutive years, from $584,000 in FY2020 to $42,000 in FY2024.
Based on SEC 10-K filings.
$42,000 in FY2024 with a 3-year CAGR of -50.2%.
Declined from $275,000 to $42,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -50.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 195This company $42.0K Sector average $117.2M
▼
-100.0% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s capital expenditures has declined for 4 consecutive years.
- 3-year CAGR of -50.2%, indicating a declining trend.
- In FY2024, capital expenditures decreased 19.2% year-over-year.
- Ranks #182 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $42.0K | -19.2% |
| FY2023 | $52.0K | -81.1% |
| FY2022 | $275.0K | -19.1% |
| FY2021 | $340.0K | -41.8% |
| FY2020 | $584.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026